A user with over two years of experience using growth hormone reported starting a new experimental regimen combining Tesamorelin and Ipamorelin. Their primary goal was to reach an IGF-1 serum range of 300-350 ng/ml while monitoring potential downregulation, though they noted limited long-term data on secretagogue efficacy for therapeutic IGF-1 levels.